S&P 500   3,324.82 (+0.12%)
DOW   29,215.23 (+0.07%)
QQQ   224.05 (+0.34%)
AAPL   317.82 (+0.39%)
FB   221.75 (+0.14%)
MSFT   165.73 (-0.46%)
GOOGL   1,487.22 (+0.34%)
AMZN   1,888.38 (-0.19%)
CGC   24.11 (-0.17%)
NVDA   250.48 (+1.02%)
BABA   222.59 (+0.15%)
MU   59.22 (+0.42%)
GE   11.40 (-2.31%)
TSLA   569.17 (+4.01%)
AMD   51.49 (+0.86%)
T   39.12 (+1.53%)
ACB   2.04 (+1.50%)
F   9.16 (-0.54%)
NFLX   325.12 (-3.84%)
PRI   126.62 (+0.17%)
BAC   34.42 (+0.47%)
DIS   144.20 (+0.44%)
GILD   63.38 (+1.18%)
S&P 500   3,324.82 (+0.12%)
DOW   29,215.23 (+0.07%)
QQQ   224.05 (+0.34%)
AAPL   317.82 (+0.39%)
FB   221.75 (+0.14%)
MSFT   165.73 (-0.46%)
GOOGL   1,487.22 (+0.34%)
AMZN   1,888.38 (-0.19%)
CGC   24.11 (-0.17%)
NVDA   250.48 (+1.02%)
BABA   222.59 (+0.15%)
MU   59.22 (+0.42%)
GE   11.40 (-2.31%)
TSLA   569.17 (+4.01%)
AMD   51.49 (+0.86%)
T   39.12 (+1.53%)
ACB   2.04 (+1.50%)
F   9.16 (-0.54%)
NFLX   325.12 (-3.84%)
PRI   126.62 (+0.17%)
BAC   34.42 (+0.47%)
DIS   144.20 (+0.44%)
GILD   63.38 (+1.18%)
S&P 500   3,324.82 (+0.12%)
DOW   29,215.23 (+0.07%)
QQQ   224.05 (+0.34%)
AAPL   317.82 (+0.39%)
FB   221.75 (+0.14%)
MSFT   165.73 (-0.46%)
GOOGL   1,487.22 (+0.34%)
AMZN   1,888.38 (-0.19%)
CGC   24.11 (-0.17%)
NVDA   250.48 (+1.02%)
BABA   222.59 (+0.15%)
MU   59.22 (+0.42%)
GE   11.40 (-2.31%)
TSLA   569.17 (+4.01%)
AMD   51.49 (+0.86%)
T   39.12 (+1.53%)
ACB   2.04 (+1.50%)
F   9.16 (-0.54%)
NFLX   325.12 (-3.84%)
PRI   126.62 (+0.17%)
BAC   34.42 (+0.47%)
DIS   144.20 (+0.44%)
GILD   63.38 (+1.18%)
S&P 500   3,324.82 (+0.12%)
DOW   29,215.23 (+0.07%)
QQQ   224.05 (+0.34%)
AAPL   317.82 (+0.39%)
FB   221.75 (+0.14%)
MSFT   165.73 (-0.46%)
GOOGL   1,487.22 (+0.34%)
AMZN   1,888.38 (-0.19%)
CGC   24.11 (-0.17%)
NVDA   250.48 (+1.02%)
BABA   222.59 (+0.15%)
MU   59.22 (+0.42%)
GE   11.40 (-2.31%)
TSLA   569.17 (+4.01%)
AMD   51.49 (+0.86%)
T   39.12 (+1.53%)
ACB   2.04 (+1.50%)
F   9.16 (-0.54%)
NFLX   325.12 (-3.84%)
PRI   126.62 (+0.17%)
BAC   34.42 (+0.47%)
DIS   144.20 (+0.44%)
GILD   63.38 (+1.18%)
Log in
(Ad)
And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

NYSE:GKOS - Glaukos Stock Price, Forecast & News

$58.10
+0.18 (+0.31 %)
(As of 01/22/2020 03:55 PM ET)
Today's Range
$58.01
Now: $58.10
$58.66
50-Day Range
$54.19
MA: $56.88
$61.09
52-Week Range
$53.19
Now: $58.10
$84.65
Volume8,794 shs
Average Volume301,682 shs
Market Capitalization$2.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone949-367-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$181.28 million
Book Value$4.98 per share

Profitability

Net Income$-12,950,000.00

Miscellaneous

Employees437
Market Cap$2.11 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%?

Wall Street legend Paul Mampilly recently identified this as the stock of the century.

Buying up a handful of shares of this small company now could change your life and even make you millions.

Glaukos (NYSE:GKOS) Frequently Asked Questions

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How were Glaukos' earnings last quarter?

Glaukos Corp (NYSE:GKOS) announced its quarterly earnings data on Wednesday, November, 6th. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.07. The medical instruments supplier earned $58.51 million during the quarter, compared to the consensus estimate of $56.96 million. Glaukos had a negative net margin of 8.60% and a negative return on equity of 4.01%. The company's quarterly revenue was up 33.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) EPS. View Glaukos' Earnings History.

When is Glaukos' next earnings date?

Glaukos is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Glaukos.

What price target have analysts set for GKOS?

9 brokerages have issued 12 month price targets for Glaukos' shares. Their forecasts range from $58.00 to $80.00. On average, they anticipate Glaukos' stock price to reach $68.89 in the next year. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for Glaukos.

What is the consensus analysts' recommendation for Glaukos?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Glaukos.

What are Wall Street analysts saying about Glaukos stock?

Here are some recent quotes from research analysts about Glaukos stock:
  • 1. According to Zacks Investment Research, "Glaukos is currently progressing with the U.S. commercial rollout of its next-generation iStent inject Trabecular Micro-Bypass device. It also initiated patient enrolment of key U.S. pivotal clinical studies for iDose Travoprost and iStent Infinite. Through continued investment and a new pharmaceutical development agreement with D. Western Therapeutic Institute Glaukos expanded its pharmaceutical capabilities. A strong pipeline is indicative of brighter prospects ahead. Management is optimistic about the recent Avedro buyout. The company outperformed the industry year-to-date. With respect to quarterly results, Glaukos exited the second quarter on a tepid note. Also, Glaukos faces cutthroat competition in the Medical Devices space. Further, an overtly stringent regulatory-approval process for the iDose platform is concerning." (9/12/2019)
  • 2. BTIG Research analysts commented, "We maintain our Neutral rating on GKOS shares following a solid 1Q19 beat. Largely expected, GKOS delivered rev. of $54.0M vs. BTIG/Street est. of $49.7M/$50.2M as iStent inject conversions and OUS strength drove upside while competitive trialing was modest (below mgmt.’s initial expectations). CyPass share gains continue to buoy US results (we est. $9M-$10M/qtr.) Current business execution, market dynamics, and pricing all appear to be in-line to slightly better than originally guided with no material change to pipeline timelines. Against a ~$4M beat, mgmt. moved the lower-end of guidance up $5M (+$2.5M at the midpoint), sticking with a conservative (but optimistic) tone through the balance of the year. Mgmt. remains cautious around an increase in competitive trialing within the US combined with continued OUS challenges in the UK stemming from reimbursement cuts." (5/10/2019)

Has Glaukos been receiving favorable news coverage?

Media headlines about GKOS stock have trended negative recently, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Glaukos earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Glaukos.

Who are some of Glaukos' key competitors?

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include PTC Therapeutics (PTCT), Alibaba Group (BABA), Paypal (PYPL), Twilio (TWLO), NVIDIA (NVDA), Caterpillar (CAT), Baidu (BIDU), Splunk (SPLK), Boeing (BA) and Coupa Software (COUP).

Who are Glaukos' key executives?

Glaukos' management team includes the folowing people:
  • Mr. Thomas William Burns, CEO, Pres & Director (Age 58)
  • Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)
  • Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)
  • Mr. Richard L. Harrison, Advisor (Age 62)
  • Dr. Mory Gharib Ph.D., Co-Founder

When did Glaukos IPO?

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.14%), Rhenman & Partners Asset Management AB (0.65%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Exchange Traded Concepts LLC (0.00%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.

Which institutional investors are buying Glaukos stock?

GKOS stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, Exchange Traded Concepts LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Glaukos.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $58.21.

How big of a company is Glaukos?

Glaukos has a market capitalization of $2.12 billion and generates $181.28 million in revenue each year. The medical instruments supplier earns $-12,950,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Glaukos employs 437 workers across the globe.View Additional Information About Glaukos.

What is Glaukos' official website?

The official website for Glaukos is http://www.glaukos.com/.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]


MarketBeat Community Rating for Glaukos (NYSE GKOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  365 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  640
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Diluted Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel